Skip to main content


Informed and effective treatments for your patients

Informed and Effective Treatments for Your Patient

What is your greatest challenge when a patient walks through your door?

If the patient is a newly diagnosed patient, for most oncologists, it is not being certain of response to standard-of-care therapy. If it is a patient for whom standard-of-care has already failed, it is determining what treatment options may be available for the patient. If the patient has a type of cancer that is poorly responsive to treatment, it is deciding the next course of action. You are dealing with situations that limit your options because of challenges in predicting responsiveness to therapy, particularly when time is limited.

Disappointing results pose treatment challenges. What has traditionally been diagnosed as a single indication via biomarkers, histology and cell morphology is now understood to be multiple disease subtypes in the context of biochemical pathways.

Over time, however, the results of targeted gene panels, the ‘one mutation, one drug’ paradigm, have been found to be of limited value for treatment decisions. The emergence of NGS helped identify broad tumor genomic profiles that provide additional data and information to oncologists. However, the clinical utility of these NGS reports has been disappointing. In addition to a patient with a confounding disease, the physician is burdened with too much indiscernible information.

Patient centric trials in precision oncology

Molecularly targeted therapy based on tumor profiling (SHIVA)

Implications of considering genomic measurements in isolation for precision medicine

Cellworks assists interpretation of heterogeneity in a patient’s tumor genomic profiling using computational mathematics and bio-simulation to create the patient’s genomic profile, and understand the biochemical molecular pathways and disease phenotypes for effective clinical outcomes. Our reports provide you with actionable suggestions, each with a transparent causative rationale.

Cellwork Precision Medicine Workflow


SingulaTM predicts whether a targeted standard-of-care (SoC) targeted drug therapy will produce response in the patient. By predictively separating responders from non-responders, the physician has an actionable decision making ability for optimized therapy. This can save vital time for the patient as well as control treatment costs.

Say you, the physician, are presented with a MDS patient who has TET1, TET2, MTHFR, MTRR, TP53, APC, AXIN2 and ASXL1 mutations and a complex cytogenetics profile with loss of various chromosomal segments. SingulaTM can help guide you whether the patient with this set of genomic aberrations is likely to respond a MDS standard-of-care drug like Azacitidine or Lenalidomide.

SingulaTM can be considered for treatment-naïve patients.

Download Sample Report for SingulaTM

Show More


Show Less


VENTURATM Ideal Combination:

After the standard-of-care therapies are exhausted, or after the patient has relapsed, the current protocol is to send the patient to clinical trials or to palliative care. Cellworks offers another option. VenturaTM informs you, the physician, of the likely ideal combination of all FDA-approved drugs to produce the response in the patient. In determining this optimal combination, on-label oncology drugs, off-label oncology drugs and non-oncology drugs are all investigated before a recommendation is made.

Say you, the physician, are presented with an AML patient who has HER2, FGFR4, IL4R, IL6R, IL7, TET1, DNMT3L mutations, and various other genes have copy number variations and are amplified (ACLY, NRG1, FGFR1, FGFR3, LYN) or deleted (TET3). VenturaTM will help guide you as to which combination of FDA-approved drugs this AML patient is likely to respond to.

VenturaTM can be considered for refractory or relapsed patients.

Download Sample Report for VenturaTM

Show More


Show Less


Engage In Improving Patient Outcomes

Start an engagement with Cellworks for your relapsed and refractory patients. You’ve already tried standard-of-care therapies for them. Sadly, they have not proven efficacious for your patient.

Participate in this paradigm shift. There are ongoing PI-initiated clinical trials that compare predictions with outcomes of cancer treatments for Multiple Myeloma, Myelodysplasia Syndrome (MDS), Acute Myeloid Leukemia, Myelofibrosis, Glioblastoma, and Waldenstrom Macroglobulinemia (WM).

Show More


Show Less


Validated. Precisely.

Cellworks's simulation predictions have been validated through cell-line studies, animal studies, human ex-vivo experiments, retrospective clinical studies and prospective clinical trials, with biomarker and phenotype trends in lab and clinical settings.

Cellworks has:

  • Participated in more than 50 global scientific collaborations
  • Conducted over 3000 prediction validations
  • Produced over 50 peer-reviewed papers and abstracts

Please Note:

A multitude of factors guide recommendations for the appropriate therapy regimen for your patient. Cellworks fully recognizes that the somatic tumor genomic profile, that goes into generating a Cellworks's recommendation, is only one small facet of the patient’s type of cancer. The Cellworks's recommendation is only one input to you. Because Cellworks's recommendations need to be viewed in the context of the patient as a whole, decisions need to be made by the physician who knows the patient best.


Information, publications and white papers at your fingertips